60 Degrees Pharmaceuticals (SXTP) Competitors

$1.65 +0.04 (+2.48%)

Closing price 04:00 PM Eastern

Extended Trading

$1.64 -0.01 (-0.91%)

As of 07:55 PM Eastern

SXTP vs. NAII, APLT, NCEL, INAB, and MAAQ

Should you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Natural Alternatives International (NAII), Applied Therapeutics (APLT), NLS Pharmaceutics (NCEL), IN8bio (INAB), and Mana Capital Acquisition (MAAQ). These companies are all part of the "pharmaceutical products" industry.

How does 60 Degrees Pharmaceuticals compare to Natural Alternatives International?

Natural Alternatives International (NASDAQ:NAII) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

: 60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Natural Alternatives International $129.86M 0.12 -$13.57M -$2.04 N/A
60 Degrees Pharmaceuticals $1.41M 3.09 -$7.36M -$13.88 N/A
: Natural Alternatives International has a net margin of -9.06% compared to 60 Degrees Pharmaceuticals' net margin of -550.67%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Natural Alternatives International's return on equity.
Company Net Margins Return on Equity Return on Assets
Natural Alternatives International -9.06% -8.60% -3.92%
60 Degrees Pharmaceuticals -550.67% N/A -132.47%
: 32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 20.8% of Natural Alternatives International shares are held by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: Natural Alternatives International has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500.
: In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Natural Alternatives International. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Natural Alternatives International. 60 Degrees Pharmaceuticals' average media sentiment score of 0.49 beat Natural Alternatives International's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Natural Alternatives International
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
60 Degrees Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 60 Degrees Pharmaceuticals has a consensus price target of $14.10, suggesting a potential upside of 754.55%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Natural Alternatives International.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natural Alternatives International
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
60 Degrees Pharmaceuticals
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.04	N/A
60 Degrees Pharmaceuticals	$1.41M	3.09	-$7.36M	-$13.88	N/A

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-9.06%	-8.60%	-3.92%
60 Degrees Pharmaceuticals	-550.67%	N/A	-132.47%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natural Alternatives International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

60 Degrees Pharmaceuticals beats Natural Alternatives International on 9 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

: Applied Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -550.67%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Applied Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Applied Therapeutics N/A -340.84% -175.00%
60 Degrees Pharmaceuticals -550.67% N/A -132.47%
: In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Applied Therapeutics. 60 Degrees Pharmaceuticals' average media sentiment score of 0.49 beat Applied Therapeutics' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
Applied Therapeutics Neutral
60 Degrees Pharmaceuticals Neutral
: Applied Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500.
: Applied Therapeutics currently has a consensus price target of $1.25, suggesting a potential upside of 1,113.59%. 60 Degrees Pharmaceuticals has a consensus price target of $14.10, suggesting a potential upside of 754.55%. Given Applied Therapeutics' higher probable upside, equities analysts plainly believe Applied Therapeutics is more favorable than 60 Degrees Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Therapeutics
1 Sell rating(s)
3 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.75
60 Degrees Pharmaceuticals
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
: 98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: 60 Degrees Pharmaceuticals has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Applied Therapeutics $1M 15.86 -$105.62M -$0.10 N/A
60 Degrees Pharmaceuticals $1.41M 3.09 -$7.36M -$13.88 N/A

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
60 Degrees Pharmaceuticals	-550.67%	N/A	-132.47%

Company	Overall Sentiment
Applied Therapeutics	Neutral
60 Degrees Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
60 Degrees Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
60 Degrees Pharmaceuticals	$1.41M	3.09	-$7.36M	-$13.88	N/A

Summary

60 Degrees Pharmaceuticals beats Applied Therapeutics on 10 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to NLS Pharmaceutics?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

: 60 Degrees Pharmaceuticals has higher revenue and earnings than NLS Pharmaceutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
60 Degrees Pharmaceuticals $1.41M 3.09 -$7.36M -$13.88 N/A
NLS Pharmaceutics N/A N/A -$8.30M N/A N/A
: 60 Degrees Pharmaceuticals presently has a consensus target price of $14.10, suggesting a potential upside of 754.55%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than NLS Pharmaceutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
NLS Pharmaceutics
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: 60 Degrees Pharmaceuticals has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
: In the previous week, NLS Pharmaceutics had 3 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 5 mentions for NLS Pharmaceutics and 2 mentions for 60 Degrees Pharmaceuticals. NLS Pharmaceutics' average media sentiment score of 1.31 beat 60 Degrees Pharmaceuticals' score of 0.49 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
60 Degrees Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
NLS Pharmaceutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: NLS Pharmaceutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -550.67%.
Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals -550.67% N/A -132.47%
NLS Pharmaceutics N/A N/A N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	3.09	-$7.36M	-$13.88	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NLS Pharmaceutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-550.67%	N/A	-132.47%
NLS Pharmaceutics	N/A	N/A	N/A

Summary

60 Degrees Pharmaceuticals beats NLS Pharmaceutics on 7 of the 12 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to IN8bio?

IN8bio (NASDAQ:INAB) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

: 60 Degrees Pharmaceuticals has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IN8bio N/A N/A -$19.44M -$4.45 N/A
60 Degrees Pharmaceuticals $1.41M 3.09 -$7.36M -$13.88 N/A
: IN8bio presently has a consensus target price of $4.00, suggesting a potential upside of 146.91%. 60 Degrees Pharmaceuticals has a consensus target price of $14.10, suggesting a potential upside of 754.55%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than IN8bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IN8bio
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
60 Degrees Pharmaceuticals
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
: 92.1% of IN8bio shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: IN8bio has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500.
: In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than IN8bio. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for IN8bio. 60 Degrees Pharmaceuticals' average media sentiment score of 0.49 beat IN8bio's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IN8bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
60 Degrees Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: IN8bio has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -550.67%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat IN8bio's return on equity.
Company Net Margins Return on Equity Return on Assets
IN8bio N/A -111.30% -88.07%
60 Degrees Pharmaceuticals -550.67% N/A -132.47%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$4.45	N/A
60 Degrees Pharmaceuticals	$1.41M	3.09	-$7.36M	-$13.88	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-111.30%	-88.07%
60 Degrees Pharmaceuticals	-550.67%	N/A	-132.47%

Summary

60 Degrees Pharmaceuticals beats IN8bio on 9 of the 14 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Mana Capital Acquisition?

Mana Capital Acquisition (NASDAQ:MAAQ) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

: Mana Capital Acquisition has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mana Capital Acquisition N/A N/A N/A N/A N/A
60 Degrees Pharmaceuticals $1.41M 3.09 -$7.36M -$13.88 N/A
: Mana Capital Acquisition has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -550.67%.
Company Net Margins Return on Equity Return on Assets
Mana Capital Acquisition N/A N/A N/A
60 Degrees Pharmaceuticals -550.67% N/A -132.47%
: 60 Degrees Pharmaceuticals has a consensus target price of $14.10, indicating a potential upside of 754.55%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Mana Capital Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mana Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
60 Degrees Pharmaceuticals
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
: 68.4% of Mana Capital Acquisition shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Mana Capital Acquisition. 60 Degrees Pharmaceuticals' average media sentiment score of 0.49 beat Mana Capital Acquisition's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
Mana Capital Acquisition Neutral
60 Degrees Pharmaceuticals Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
60 Degrees Pharmaceuticals	$1.41M	3.09	-$7.36M	-$13.88	N/A

Company	Net Margins	Return on Equity	Return on Assets
Mana Capital Acquisition	N/A	N/A	N/A
60 Degrees Pharmaceuticals	-550.67%	N/A	-132.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Overall Sentiment
Mana Capital Acquisition	Neutral
60 Degrees Pharmaceuticals	Neutral

Summary

60 Degrees Pharmaceuticals beats Mana Capital Acquisition on 7 of the 10 factors compared between the two stocks.

Get 60 Degrees Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SXTP vs. The Competition

Export

Metric	60 Degrees Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.25M	$3.10B	$6.24B	$11.86B
Dividend Yield	N/A	1.91%	2.73%	5.21%
P/E Ratio	N/A	18.37	29.04	28.48
Price / Sales	3.09	272.31	477.10	60.43
Price / Cash	N/A	50.43	27.62	36.52
Price / Book	-0.28	4.33	9.67	6.67
Net Income	-$7.36M	$72.19M	$3.55B	$332.64M
7 Day Performance	3.12%	2.03%	1.70%	2.01%
1 Month Performance	-11.29%	6.42%	5.62%	9.19%
1 Year Performance	-82.59%	37.74%	34.42%	39.59%

60 Degrees Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SXTP 60 Degrees Pharmaceuticals	1.9377 of 5 stars	$1.65 +2.5%	$14.10 +754.5%	N/A	$4.25M	$1.41M	N/A	3
NAII Natural Alternatives International	1.0363 of 5 stars	$2.67 -0.4%	N/A	N/A	$16.50M	$129.86M	N/A	290	News Coverage Positive News Upcoming Earnings Gap Up
APLT Applied Therapeutics	1.2863 of 5 stars	$0.10 flat	$1.25 +1,113.6%	N/A	$15.86M	$1M	N/A	30
NCEL NLS Pharmaceutics	1.1775 of 5 stars	$3.42 +2.1%	N/A	N/A	$15.60M	N/A	N/A	6	Positive News
INAB IN8bio	2.0422 of 5 stars	$1.51 -1.3%	$4.00 +164.9%	N/A	$14.87M	N/A	N/A	20	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SXTP) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. NAII, APLT, NCEL, INAB, and MAAQ

How does 60 Degrees Pharmaceuticals compare to Natural Alternatives International?

Summary

How does 60 Degrees Pharmaceuticals compare to Applied Therapeutics?

Summary

How does 60 Degrees Pharmaceuticals compare to NLS Pharmaceutics?

Summary

How does 60 Degrees Pharmaceuticals compare to IN8bio?

Summary

How does 60 Degrees Pharmaceuticals compare to Mana Capital Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. NAII, APLT, NCEL, INAB, and MAAQ

How does 60 Degrees Pharmaceuticals compare to Natural Alternatives International?

Summary

How does 60 Degrees Pharmaceuticals compare to Applied Therapeutics?

Summary

How does 60 Degrees Pharmaceuticals compare to NLS Pharmaceutics?

Summary

How does 60 Degrees Pharmaceuticals compare to IN8bio?

Summary

How does 60 Degrees Pharmaceuticals compare to Mana Capital Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools